+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

What constitutes high-risk locally advanced prostate cancer?



What constitutes high-risk locally advanced prostate cancer?



Clinical Genitourinary Cancer 4(3): 193-196



Excluding basal and squamous cell cancers of the skin, prostate cancer is the most common malignancy diagnosed in the United States. With increasing awareness and routine prostate-specific antigen testing, a remarkable migration in the clinical presentation of the disease has occurred in the past 20 years. An increasingly greater proportion of men are diagnosed with clinically organ-confined disease. In parallel, the incidence of men presenting with clinically bulky locoregional or metastatic disease has decreased. Despite the stage migration, when clinical and pathologic parameters are taken into account, a significant number of men with clinically localized prostate cancer do not have truly organ-confined disease. Such men might not to be cured with single modality, locally directed therapies. Thus, prostate cancer represents a disease spectrum with a number of biologic and clinical factors determining disease extent. An overview of some of these aspects of the disease is presented.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 050969349

Download citation: RISBibTeXText

PMID: 16425988

DOI: 10.3816/CGC.2005.n.032


Related references

Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO. Der Urologe. Ausg. A 56(2): 243-244, 2017

Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer. Clinical Oncology ()) 28(6): 376-385, 2016

Management of high-risk populations with locally advanced prostate cancer. Oncologist 8(3): 259-269, 2003

ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer. American Journal of Clinical Oncology 40(1): 1-10, 2017

Current treatment in high risk and locally advanced prostate cancer. Actas Urologicas Espanolas 31(5): 445-451, 2007

The importance of surgery in locally advanced very high risk prostate cancer. European Urology Supplements 15(11): E1402-E1403, 2016

The management of high-risk, locally advanced, prostate cancer radiation therapy. Canadian Urological Association Journal 6(5): 393-395, 2012

The importance of local control in high-risk locally advanced prostate cancer. Current Oncology 19(Suppl 3): S6-S12, 2013

Radiotherapy before and after radical prostatectomy for high-risk and locally advanced prostate cancer. Urologic Oncology 33(5): 226-234, 2016

Man With Locally Advanced, High-Risk Prostate Cancer Asks About Adding Chemotherapy to His Treatment. Oncology 30(1): 94-98, 2016

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 61(4): 774-780, April, 2003

Locally advanced and high risk prostate cancer: The best indication for initial radical prostatectomy?. Asian Journal of Urology 1(1): 40-45, 2018

Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. Urologic Oncology 33(5): 235-244, 2016

American College of Radiology Appropriateness Criteria(®)--locally advanced (high-risk) prostate cancer. Clinical Oncology ) 24(1): 43-51, 2012

Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology 215 Suppl: 1401-1412, 2000